<DOC>
	<DOCNO>NCT00287183</DOCNO>
	<brief_summary>Current research indicate TTP488 may viable agent treatment diabetic nephropathy . The purpose study determine safety efficacy six-month regimen daily orally-administered TTP488 patient diabetic nephropathy .</brief_summary>
	<brief_title>6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>Male female outpatient 31 year age old . Females must longer childbearing potential , must negative serum pregnancy test , breastfeed . Nonvasectomized male must willing abstain sexual intercourse willing use condom addition female partner use another form contraception . Diagnosis probable Type 2 diabetes age 30 least 6 month prior screen visit : requiring insulin within first year diagnosis ; history diabetic ketoacidosis ( DKA ) ; body mass index ( BMI ) 40 less screen visit Presence persistent albuminuria UACR 6.7 203 mg/mmol Must take high tolerate dose angiotensin convert enzyme ( ACE ) inhibitor angiotensin II receptor blocker ( ARB ) maintain dose least 3 month prior Baseline visit Blood pressure ( BP ) must stable well controlled judgement investigator ( goal control BP 130/80 less ) . If require , use antihypertensive addition ACE inhibitor ARB acceptable . Patients calculate creatinine clearance great equal 30 mL/min without presence clinically significant hematuria red white cell cast include study . Diagnosis Type 1 diabetes Hemoglobin A1c ( HbA1c ) &gt; 10 % Females breastfeed Known renal artery stenosis Calculated creatinine clearance &lt; 30 mL/min presence clinically significant hematuria red white cell cast Chronic use NSAIDs 1 g/day aspirin QTc &gt; 450 msec female &gt; 430 msec male ( measure time start Q wave end T wave heart 's electrical cycle ) Known family history prolong QT syndrome History symptomatic congestive heart failure within last 2 year History syncope lst 2 year recurrent hypokalemia , include cause diuretic Myocardial infarction sign symptom unstable coronary artery disease last year Pulmonary disease evidence clinically significant pulmonary symptom . Active neoplastic disease . ( Excised cutaneous basal cell carcinoma exclude ) . Patients stable prostate cancer may include discretion Medical Monitor . Any clinically significant hematologic coagulation disorder Any clinically significant hepatic disease Use exclude medication : drug know significantly increase QTc and/or increase risk torsades de point , immunosuppressive agent , cancer chemotherapeutic agent , oral corticosteroid maintenance dose equivalent 7.5 mg prednisone per day , radiotherapy Use investigational drug within 30 day within 5 halflives investigational agent , whichever longer , use investigational medical device within 2 week study Any disease condition , opinion investigator , make patient unsuitable participate study</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>